The human airway epithelium occupy a central position in the pathogenesis of respiratory viruses. As the first line of defense against microorganisms, epithelia cells reacts through mucus secretion, mucociliary clearance, activation and release of chemokines, cytokines, lipids, growth factors, proteases, etc.

Viral respiratory infections are the most frequent etiologies of acute illnesses worldwide and cause mild to severe diseases such as common cold, bronchiolitis and pneumonia. A comparative study was carried out on the infectivity and replication of the most frequent human respiratory viruses using standardized *in vitro* reconstituted human airway epithelia (MucilAir™). Differentiated tissues were infected in parallel with clinically relevant strains of rhinovirus (A16, A49, A55, B48, C8, C15), respiratory enterovirus (EV68), influenza virus (H3N2) and corona virus (OC43). For each virus, replication kinetics, cell tropism, impact of the virus on tissue integrity and cilia function were assessed.

Development and use of anti-viral drugs are one of the priorities for major pharmaceutical companies. As proof-of-concept for drug screening, the efficacy of Rupintruvir and Oseltamivir were tested in MucilAir™. Rupintruvir efficiently inhibited the replication of HRV-A16 and HRV-C15 in a dose and time dependent manner (up to 99% inhibition). Interestingly, (i) Oseltamivir reduced the replication of H1N1 and H3N2 and restored the impaired barrier function monitored by Trans-Epithelial Electrical Resistance and (ii) Rupintivir restored the mucociliary clearance impaired by EV68 (7 μm/s for the Mock up to 40 μm/s for the Rupintrivir treatment at 50 nM at 96 h post innoculation).

These results demonstrated that MucilAir™ is a robust, reliable and relevant tool for antiviral drug development.
